Sotorasib: First Approval - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34357500/

Sotorasib (LUMAKRAS ™ ) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatme ...